This first clinical study investigating the potential of GM-CSF to improve collateral flow in patients with coronary artery disease documents its efficacy in a short-term administration protocol.
No takes yet. Share an insight, caveat, or question.
Seiler et al. (2001) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: